The stock of Bio-Techne Corporation (NASDAQ:TECH) reached all time high today, Jun, 17 and still has $172.20 target or 4.00% above today’s $165.58 share price. This indicates more upside for the $6.22B company. This technical setup was reported by Barchart.com. If the $172.20 PT is reached, the company will be worth $248.84 million more. The stock increased 0.93% or $1.52 during the last trading session, reaching $165.58. About 252,054 shares traded or 46.52% up from the average. Bio-Techne Corporation (NASDAQ:TECH) has risen 33.83% since June 17, 2017 and is uptrending. It has outperformed by 21.26% the S&P500. Some Historical TECH News: ; 26/04/2018 – Bio-Techne Leads the Way in Scientific Support for Autophagy Research; 02/05/2018 – Bio-Techne 3Q Adj EPS $1.21; 14/03/2018 Bio-Techne Launches MimEX™ GI, an Accessible 3-D Cell Culturing Platform for the Gastrointestinal Tract; 10/04/2018 – Bio-Techne at Deutsche Bank Health Care Conference May 8; 24/04/2018 – Bio-Techne Names Kim Kelderman as Pres, Diagnostics and Genomics; 21/03/2018 – Bio-Techne Expands RNAscope® ISH Automation – Facilitating Drug Discovery and Development; 22/04/2018 – DJ Bio-Techne Corporation, Inst Holders, 1Q 2018 (TECH); 07/05/2018 – Bio-Techne at Deutsche Bank Health Care Conference Tomorrow
Among 5 analysts covering Neogen (NASDAQ:NEOG), 0 have Buy rating, 0 Sell and 5 Hold. Therefore 0 are positive. Neogen had 7 analyst reports since August 26, 2015 according to SRatingsIntel. As per Tuesday, September 22, the company rating was downgraded by Zacks. Stephens maintained Neogen Corporation (NASDAQ:NEOG) rating on Monday, March 26. Stephens has “Hold” rating and $6500 target. The stock has “Buy” rating by Zacks on Wednesday, August 26. The firm has “Hold” rating given on Thursday, January 4 by Roth Capital. On Tuesday, December 22 the stock rating was downgraded by Craig Hallum to “Hold”. See Neogen Corporation (NASDAQ:NEOG) latest ratings:
26/03/2018 Broker: Stephens Rating: Hold New Target: $65.0000 Maintain
04/01/2018 Broker: Roth Capital Rating: Hold New Target: $62.0 Maintain
Since January 26, 2018, it had 0 insider buys, and 16 selling transactions for $10.42 million activity. Another trade for 6,000 shares valued at $358,320 was made by PAPESH G BRUCE on Friday, January 26. HERBERT JAMES L also sold $574,954 worth of Neogen Corporation (NASDAQ:NEOG) on Thursday, February 15. MORRICAL TERRI A sold $1.00M worth of Neogen Corporation (NASDAQ:NEOG) on Friday, April 6. Quinlan Steven J. had sold 5,000 shares worth $330,648 on Tuesday, March 27. $374,818 worth of Neogen Corporation (NASDAQ:NEOG) was sold by REED THOMAS H. The insider BRADLEY EDWARD sold 11,725 shares worth $706,950. Shares for $34,920 were sold by BOEHM WILLIAM T on Wednesday, April 18.
The stock increased 1.58% or $1.27 during the last trading session, reaching $81.88. About 220,226 shares traded or 7.30% up from the average. Neogen Corporation (NASDAQ:NEOG) has risen 56.69% since June 17, 2017 and is uptrending. It has outperformed by 44.12% the S&P500. Some Historical NEOG News: ; 20/04/2018 – DJ Neogen Corporation, Inst Holders, 1Q 2018 (NEOG); 22/03/2018 – Neogen 3Q EPS 32c; 22/03/2018 – NEOGEN 3Q SPLIT ADJ. EPS 32C; 22/03/2018 – Neogen 3Q Rev $95.9M; 06/04/2018 – Hagedorn named Neogen VP of food safety operations; 22/03/2018 – NEOGEN 3Q EPS 32C, EST. 23C; 22/03/2018 – NEOGEN CORP NEOG.O : CRAIG-HALLUM RAISES TARGET PRICE TO $65 FROM $63; RATING HOLD; 17/05/2018 – Consolidated Research: 2018 Summary Expectations for TrueCar, Roadrunner Transportation, Eldorado Gold, Neogen, Ashford Hospita; 06/04/2018 – Jerome Hagedorn Named Neogen VP of Food Safety Ops; 22/03/2018 NEOGEN 3Q REV. $95.9M, EST. $97.9M
More recent Neogen Corporation (NASDAQ:NEOG) news were published by: Nasdaq.com which released: “Market Trends Toward New Normal in Neogen, Intuitive Surgical, IDT, Government Properties Income Trust, Everbridge …” on June 13, 2018. Also Benzinga.com published the news titled: “Benzinga’s Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid …” on June 15, 2018. Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: Clinical Hold For Crispr, Gilead Study Meets Endpoint, Akers Gets Grace Time” with publication date: June 01, 2018 was also an interesting one.
Investors sentiment increased to 6.71 in Q1 2018. Its up 5.22, from 1.49 in 2017Q4. It increased, as 13 investors sold Neogen Corporation shares while 15 reduced holdings. 27 funds opened positions while 161 raised stakes. 90.94 million shares or 167.86% more from 33.95 million shares in 2017Q4 were reported. Pnc Financial Svcs Group holds 948,591 shares. 6.47 million are held by Blackrock. Great Lakes Advsrs Limited Liability Com holds 100,648 shares or 0.16% of its portfolio. Cortina Asset Management Limited Liability owns 404,345 shares for 1.33% of their portfolio. Huntington Comml Bank reported 1,186 shares stake. Thomson Horstmann Bryant Inc reported 0.25% of its portfolio in Neogen Corporation (NASDAQ:NEOG). 394 are held by Greenleaf Trust. Cookson Peirce And Inc holds 8,407 shares or 0.05% of its portfolio. Mutual Of America Mngmt Ltd reported 0.05% stake. California Pub Employees Retirement Sys reported 131,853 shares. Strs Ohio has invested 0% in Neogen Corporation (NASDAQ:NEOG). First Trust Advsr Lp holds 27,845 shares. Tirschwell And Loewy holds 4.23% in Neogen Corporation (NASDAQ:NEOG) or 458,846 shares. Envestnet Asset Inc stated it has 0.01% of its portfolio in Neogen Corporation (NASDAQ:NEOG). Liberty Cap Management owns 49,403 shares for 2% of their portfolio.
Neogen Corporation, together with its subsidiaries, develops, makes, and markets various products for food and animal safety worldwide. The company has market cap of $4.22 billion. It operates through two divisions, Food Safety and Animal Safety. It has a 72.72 P/E ratio. The Food Safety segment primarily offers diagnostic test kits and complementary to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells.
More notable recent Bio-Techne Corporation (NASDAQ:TECH) news were published by: Investorplace.com which released: “Is Oracle Corporation’s Drop Your Chance to Load Up?” on June 17, 2018, also Benzinga.com with their article: “Benzinga’s Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid …” published on June 15, 2018, Realmoney.Thestreet.com published: “Jim Cramer: Tech Can’t Do it All Alone” on June 05, 2018. More interesting news about Bio-Techne Corporation (NASDAQ:TECH) were released by: Benzinga.com and their article: “Benzinga’s Top Upgrades, Downgrades For June 15, 2018” published on June 15, 2018 as well as Streetinsider.com‘s news article titled: “Bio-Techne (TECH) to Acquire Quad Technologies” with publication date: June 07, 2018.
Bio-Techne Corporation, together with its subsidiaries, develops, makes, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. The company has market cap of $6.22 billion. It operates through three divisions: Biotechnology, Protein Platforms, and Diagnostics. It has a 55.94 P/E ratio. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets.
Analysts await Bio-Techne Corporation (NASDAQ:TECH) to report earnings on August, 14. They expect $1.18 EPS, up 15.69% or $0.16 from last year’s $1.02 per share. TECH’s profit will be $44.33 million for 35.08 P/E if the $1.18 EPS becomes a reality. After $1.13 actual EPS reported by Bio-Techne Corporation for the previous quarter, Wall Street now forecasts 4.42% EPS growth.
Among 10 analysts covering BIO-TECHNE Corp (NASDAQ:TECH), 6 have Buy rating, 0 Sell and 4 Hold. Therefore 60% are positive. BIO-TECHNE Corp had 26 analyst reports since August 18, 2015 according to SRatingsIntel. The stock has “Outperform” rating by Leerink Swann on Thursday, November 10. As per Tuesday, August 18, the company rating was upgraded by Zacks. Deutsche Bank maintained the shares of TECH in report on Wednesday, August 9 with “Buy” rating. The stock of Bio-Techne Corporation (NASDAQ:TECH) has “Sell” rating given on Tuesday, September 1 by Zacks. The company was maintained on Wednesday, February 7 by Craig Hallum. The rating was maintained by Deutsche Bank on Thursday, May 3 with “Buy”. The stock of Bio-Techne Corporation (NASDAQ:TECH) earned “Buy” rating by Robert W. Baird on Tuesday, October 31. Wells Fargo initiated Bio-Techne Corporation (NASDAQ:TECH) on Thursday, July 13 with “Hold” rating. The stock of Bio-Techne Corporation (NASDAQ:TECH) earned “Buy” rating by Robert W. Baird on Monday, October 23. The firm has “Buy” rating given on Tuesday, May 3 by Janney Capital.